Access and Utilization of New Antidepressant and Antipsychotic Medications. Chapter VIII. Future Directions in the Benefits Status of Psychotherapeutic Pharmaceuticals

01/01/2000

The present study provides a single snapshot of a landscape that is rapidly changing. Numerous factors are affecting the structure of the health care payment system in the United States and the combination of these will likely result in a vastly different state of access to and utilization of pharmaceuticals in general and psychotherapeutics specifically. We believe that the principal factors include:

  • The appearance of new chemical entities and generic competition to the current class of "new" psychotherapeutic medications;
  • The changing understanding of the formulary by health care payers;
  • The emergence of "three-tier" copayment schemes;
  • The growth of mental health parity legislation; and
  • Continued change in the structure of managed care and regulatory steps to assure quality.